Tegafur

dihydropyrimidine dehydrogenase ; Homo sapiens







27 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 30944635 5-Fluorouracil-based adjuvant chemotherapy improves the clinical outcomes of patients with lymphovascular invasion of upper urinary tract cancer and low expression of dihydropyrimidine dehydrogenase. 2019 May 2
2 28835573 Higher Tissue Levels of Thymidylate Synthase Determined by ELISA Are Associated with Poor Prognosis of Patients with Lung Cancer. 2017 Aug 1
3 26651493 Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: a lethal case with a new variant. 2016 1
4 23585145 Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule. 2013 Aug 2
5 28520376 Fluorouracil Therapy and DPYD Genotype 2012 1
6 21378348 A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil. 2011 Feb 1
7 20146975 [Dihydropyrimidine dehydrogenase deficiency and toxicity to fluoropyrimidine]. 2010 Jan-Feb 4
8 19015148 Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung. 2009 Jan 2
9 17143493 Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase. 2007 Jan 2
10 17603216 Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium. 2007 Jun 4
11 17695427 Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer. 2007 Jul-Aug 1
12 17952005 Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer. 2007 1
13 16897969 [Pharmacokinetics of S-1]. 2006 Jun 4
14 16897985 Rapid development of S-1 in the west for therapy of advanced gastric carcinoma. 2006 Jun 2
15 15598584 Dihydropyrimidine dehydrogenase expression predicts survival outcome and chemosensitivity to 5-fluorouracil in patients with oral squamous cell carcinoma. 2005 Jan 2
16 15363468 The role of uracil-tegafur (UFT) in elderly patients with colorectal cancer. 2004 Oct 2
17 12775012 S-1 in gastric cancer: a comprehensive review. 2003 1
18 12851836 Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. 2003 Jun 2
19 14551502 Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer. 2003 Oct 1
20 12111108 Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. 2002 Jul 2
21 12355409 Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer. 2002 Oct 2
22 12464897 Thymidylate synthase and dihydropyrimidine dehydrogenase expression in oral squamous cell carcinoma: an immunohistochemical and clinicopathologic study. 2002 Dec 1
23 11219978 UFT in the treatment of colorectal and breast cancer. 2001 Jan 2
24 11679189 The role of UFT and the combination of UFT/leucovorin in non-small cell lung cancer. 2001 Nov 1
25 11729480 [Dihydropyrimidine dehydrogenase activity in urothelial cancer--influence of UFT administration on DPD activity]. 2001 Nov 1
26 10473078 Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. 1999 Aug 4
27 10595802 Novel oral fluoropyrimidines in the treatment of metastatic colorectal cancer. 1999 Dec 1 2